The lowest-cost COX-2 inhibitor available through the US Medicare drug discount card programme is Merck's rofecoxib [Vioxx]

Author：

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.453, 2004-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Merck to pay $US58m in Vioxx settlement

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 555, 2008-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Open conflict on the handling of the Merck drug Vioxx by editorial giants

By Edwards RG

Reproductive BioMedicine Online, Vol. 13, Iss. 6, 2006-12 ,pp. : 905-905

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor potentiates the anticonvulsant activity of tiagabine against pentylenetetrazol-induced convulsions in mice

By Dhir A. Kulkarni S.

Inflammopharmacology, Vol. 14, Iss. 5-6, 2006-12 ,pp. : 222-225

Springer Publishing Company

Access to resources Recommend Favorite

Drug discount cards for the US

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 357, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Induction of intestinal damage by rofecoxib, the selective COX-2 inhibitor, under inhibition of nitric oxide production in rats

By Ohno Ryoko Miyazawa Tohru Hayashi Yujiro Kanatsu Kenji Tanaka Akiko Takeuchi Koji

Inflammopharmacology, Vol. 10, Iss. 4-6, 2002-12 ,pp. : 435-447

VSP

Access to resources Recommend Favorite